Ciclesonide nasal aerosol: Preliminary Phase III data

Preliminary data from a double-blind trial in 707 adult and adolescent patients >=13 years old showed that 80 or 160 ug/day Omnaris HFA met the primary endpoint of significantly reducing the 24-hour r...